New vaccine effective in preventing TB in African patients with HIV infection


Listen to the podcast: New vaccine effective in preventing TB

[[{“type”:“media”,“view_mode”:“media_large”,“fid”:null,“attributes”:{“class”:“media-image size-full wp-image-3047 ”,“typeof”:“foaf:Image”,“style”:“”,“width”:“250”,“height”:“293”,“alt”:“Fordham von Reyn”}}]] Fordham von Reyn

Investigators from Dartmouth Medical School (DMS) have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection. The DarDar Health Study, named for Dartmouth and Dar es Salaam, Tanzania, found that MV immunization reduced the rate of definite tuberculosis by 39 percent among 2,000 HIV-infected patients in Tanzania. Principal Investigator Ford von Reyn, M.D., director of the DarDar International Programs for the Section on Infectious Disease and International Health at DMS discusses the development of the vaccine.

Related links:

Susan Knapp